EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials

Sayeda Kamrun Naher iD, David Espinoza, Peter Grimison, Kohei Shitara, Nick Pavlakis, David Goldstein, Martin R Stockler, Rebecca Mercieca-Bebber, Katrin Marie Sjoquist

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01654-2 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Gastric Cancer, 2025. Verfasst von Sayeda Kamrun Naher und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, the University of Sydney, Sydney, NSW, Australia. Sayeda.naher@health.nsw.gov.au. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophageal Neoplasms, Patient Reported Outcome Measures. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, The University of Sydney.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We developed and validated a prognostic model incorporating readily accessible clinicopathological data and specific patient-reported outcomes (PROs).

Methods

We used data from two randomized trials comparing regorafenib to placebo: AGITG INTEGRATE IIa ( n = 251) for model development and AGITG INTEGRATE ( n = 152) for validation. Candidate variables were chosen from a systematic literature review and expert consultation. Significant prognostic factors in the multivariable model were identified using univariable Cox proportional hazards models with a p -value of < 0.1. Multivariable Cox proportional hazards models were developed using clinicopathological and PRO variables, with model selection refined using least absolute shrinkage and selection operator (LASSO). The model’s discrimination and calibration were assessed using concordance indices (C-statistics) and calibration plots.

Results

Univariable analysis identified 9 clinicopathological variables and 4 PRO domains that were prognostic for overall survival: body mass index (BMI), ECOG performance status, number of metastatic sites, liver involvement, treatment with regorafenib, neutrophil–lymphocyte ratio (NLR), LDH, albumin, CA 19–9, appetite loss, constipation, fatigue, and pain. The initial multivariable model (M1) incorporated geographic region (Asia vs non-Asia), performance status, number of metastatic sites, treatment with regorafenib, NLR, BMI, LDH, CA 19–9, and albumin. The preferred multivariable model (M2), including the abovementioned variables plus the 4 PROs, demonstrated superior discriminative ability with higher C-statistic values than models without PROs. Plots supported the model’s calibration.

Conclusions

Incorporating PROs into prognostic models for AGOC improved the accuracy of survival predictions. Further research is needed to validate its use in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEsophageal NeoplasmsPatient Reported Outcome MeasuresHumansPrognosisRandomized Controlled Trials as TopicFemaleMaleMiddle AgedPhenylurea CompoundsPyridinesAgedSurvival RateProportional Hazards Models

Stichwörter der Autor:innen

Gastric cancerPatient reported outcomesPrognostic modelValidation

Substanzen

regorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • NHMRC Clinical Trials Centre, the University of Sydney, Sydney, NSW, Australia. Sayeda.naher@health.nsw.gov.au.
  • NHMRC Clinical Trials Centre, the University of Sydney, Sydney, NSW, Australia.
  • Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
  • Gastrointestinal Oncology, Department of National Cancer Centre Hospital East, Chiba, Japan.
  • Royal North Shore Hospital, St Leonards, NSW, Australia.
  • Prince of Wales Hospital, University of New South Wales, Sydney, Australia.

ORCID-Profile: Sayeda Kamrun Naher

Förderung

  • National Health and Medical Research Council
  • The University of Sydney

Zitieren

APA

Naher, S. K., Espinoza, D., Grimison, P., Shitara, K., Pavlakis, N., Goldstein, D., Stockler, M. R., Mercieca-Bebber, R., & Sjoquist, K. M. (2025). Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials. Gastric Cancer. https://doi.org/10.1007/s10120-025-01654-2

Vancouver

Naher SK, Espinoza D, Grimison P, Shitara K, Pavlakis N, Goldstein D, et al. Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials. Gastric Cancer. 2025. doi:10.1007/s10120-025-01654-2

BibTeX
@article{Naher2025,
  author = {Naher, Sayeda Kamrun and Espinoza, David and Grimison, Peter and Shitara, Kohei and Pavlakis, Nick and Goldstein, David and Stockler, Martin R and Mercieca-Bebber, Rebecca and Sjoquist, Katrin Marie},
  title = {Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01654-2}
}
Kostenlos starten →